Last quarter's increase in revenue was said to be about half price increase and half new accounts.
The price increase should further be realized in tmws report as due to priciing agreements the effects of an increase take months before they show up.
Continued growth in accounts should increase at an accelerated rate as those doctors prescribing see the drugs results. Plus the continued educational campaign by svnt, admittedly the lack of such crippled the initial launch, should also contribute to account growth.
The reorganizational plan should show us significant cost decreases as it took effect in september. Management predicted a $45-50 million in annual savings by 2013. Which is over $12mil. a quarter. Even if only have of that were recognizdd in 4Q12, that would represent very significant savings.
So not even considering SOBI, europe, label extension, etc.. we should be seeing good news.